394 related articles for article (PubMed ID: 18980022)
1. Understanding and treating triple-negative breast cancer.
Anders C; Carey LA
Oncology (Williston Park); 2008 Oct; 22(11):1233-9; discussion 1239-40, 1243. PubMed ID: 18980022
[TBL] [Abstract][Full Text] [Related]
2. Triple negative breast cancer: from molecular portrait to therapeutic intervention.
Carotenuto P; Roma C; Rachiglio AM; Botti G; D'Alessio A; Normanno N
Crit Rev Eukaryot Gene Expr; 2010; 20(1):17-34. PubMed ID: 20528735
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer: an unmet medical need.
Hudis CA; Gianni L
Oncologist; 2011; 16 Suppl 1():1-11. PubMed ID: 21278435
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
5. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
6. Metastatic triple-negative breast cancer.
Rakha EA; Chan S
Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
[TBL] [Abstract][Full Text] [Related]
7. Targeting triple negative breast cancer: is p53 the answer?
Turner N; Moretti E; Siclari O; Migliaccio I; Santarpia L; D'Incalci M; Piccolo S; Veronesi A; Zambelli A; Del Sal G; Di Leo A
Cancer Treat Rev; 2013 Aug; 39(5):541-50. PubMed ID: 23321033
[TBL] [Abstract][Full Text] [Related]
8. What is triple-negative breast cancer?
Irvin WJ; Carey LA
Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
[TBL] [Abstract][Full Text] [Related]
9. Triple negative tumours: a critical review.
Reis-Filho JS; Tutt AN
Histopathology; 2008 Jan; 52(1):108-18. PubMed ID: 18171422
[TBL] [Abstract][Full Text] [Related]
10. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for triple-negative breast cancer: where are we?
Duffy MJ; McGowan PM; Crown J
Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
[TBL] [Abstract][Full Text] [Related]
12. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
Anders CK; Carey LA
Clin Breast Cancer; 2009 Jun; 9 Suppl 2(Suppl 2):S73-81. PubMed ID: 19596646
[TBL] [Abstract][Full Text] [Related]
13. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
14. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
15. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
16. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
17. ER-/PR+/HER2- breast cancer type shows the highest proliferative activity among all other combined phenotypes and is more common in young patients: Experience with 6643 breast cancer cases.
Arena V; Pennacchia I; Vecchio FM; Carbone A
Breast J; 2019 May; 25(3):381-385. PubMed ID: 30916428
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials in triple negative breast cancer.
Reeder-Hayes KE; Carey LA; Sikov WM
Breast Dis; 2010; 32(1-2):123-36. PubMed ID: 21778571
[TBL] [Abstract][Full Text] [Related]
19. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
[TBL] [Abstract][Full Text] [Related]
20. Molecularly targeted therapies for metastatic triple-negative breast cancer.
Bayraktar S; Glück S
Breast Cancer Res Treat; 2013 Feb; 138(1):21-35. PubMed ID: 23358903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]